Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse Events  J. Alfred Witjes, Joan Palou, Mark.

Slides:



Advertisements
Similar presentations
Pascal Rischmann  European Urology Supplements 
Advertisements

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management  Michael O’Leary  European Urology Supplements 
Treatment Strategies in Advanced Prostate Cancer/Genitourinary Malignancies: The Use of Bisphosphonates Across the Continuum  John M. Fitzpatrick, Marc.
Prostate Cancer 2008: Challenges in Diagnosis and Management
Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder.
Management of Acute and Chronic Retention in Men
Robotic Cystectomy Versus Open Cystectomy: Are We There Yet?
Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer  Marc Colombel, Mark Soloway, Hideyuki Akaza, Andreas Böhle, Joan Palou, Roger.
Bladder Cancer: Management and Future Directions
Holly Reid, BS, Savina Aneja, MD, Susan Y. Chon, MD  JAAD Case Reports 
Volume 73, Issue 5, Pages (May 2018)
Mark A. Nyman, M.D., Nina M. Schwenk, M.D., Marc D. Silverstein, M.D. 
Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer  Marc Colombel, Mark Soloway, Hideyuki Akaza, Andreas Böhle, Joan Palou, Roger.
What is New in Bladder Cancer Diagnosis and Management?
Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer  Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Back to the Future: Introduction and Conclusions
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Long-Term Management of Overactive Bladder with Antimuscarinic Agents
Volume 64, Issue 4, Pages (October 2013)
Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer  Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
An Update of Current Practice in Hypospadias Surgery
Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non–muscle-invasive Bladder Cancer: Results of a Multicenter,
Richard C. Harkaway  European Urology Supplements 
Volume 50, Issue 3, Pages (September 2006)
Optimising Hormone Therapy in Advanced Disease
Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer: Comparison of Current Guidelines and Recommendations  Raj Persad, Donald Lamm,
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Ian Milsom  European Urology Supplements 
The Importance of Testosterone Control in Prostate Cancer
Jacques Irani  European Urology Supplements 
Optimal Testosterone Control and Eligard®
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Neal Shore  European Urology Supplements 
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Long-Term Hormonal Therapy: Who Would Benefit?
Bladder Cancer: Highlights from 2006
The Hallmarks of BPH Progression and Risk Factors
Sergio Bracarda  European Urology Supplements 
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Pharmacotherapy in Stress and Mixed Incontinence
Christian Stief  European Urology Supplements 
Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma  Fred Saad  European Urology.
New Trends in Managing the Prostate Cancer Patient
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Who Forms Stones and Why?
Prostate Cancer 2008: Challenges in Diagnosis and Management
Martin Michel, Jean de la Rosette  European Urology Supplements 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Richard Berges  European Urology Supplements 
Profile of Silodosin European Urology Supplements
Robotic Cystectomy Versus Open Cystectomy: Are We There Yet?
Volume 52, Issue 4, Pages (October 2007)
The Benefits of Dual Inhibition of 5α Reductase
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Testim® Gel: Review of Clinical Data
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Joaquim Bellmunt  European Urology Supplements 
Classification of Mixed Incontinence
The Impact of Premature Ejaculation on Partners and Relationships
Emmanuel Chartier-Kastler, Andrea Tubaro  European Urology Supplements 
Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice 
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Jan Roigas  European Urology Supplements 
Michael Marberger  European Urology Supplements 
Presentation transcript:

Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse Events  J. Alfred Witjes, Joan Palou, Mark Soloway, Donald Lamm, Maurizio Brausi, J. Roan Spermon, Raj Persad, Roger Buckley, Hideyuki Akaza, Marc Colombel, Andreas Böhle  European Urology Supplements  Volume 7, Issue 10, Pages 667-674 (October 2008) DOI: 10.1016/j.eursup.2008.08.001 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Percentage of patients with at least one class 3 adverse event between instillations 1 and 9. Abbreviations: AE: adverse event; BCG: bacillus Calmette-Guérin. Reproduced with permission from the American Urological Association [27]. European Urology Supplements 2008 7, 667-674DOI: (10.1016/j.eursup.2008.08.001) Copyright © 2008 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.